Skip to main content
GYRE
NASDAQ Life Sciences

Gyre Therapeutics 以全股票交易的方式收购 Cullgen，交易金额约为 3 亿美元，增加蛋白质降解平台

feedReported by Reuters
Sentiment info
Positive
Importance info
9
Price
$7.6
Mkt Cap
$748.937M
52W Low
$6.11
52W High
$13.75
Market data snapshot near publication time

summarizeSummary

Gyre Therapeutics 已经签署协议，以全股票交易的方式收购 Cullgen，交易金额约为 3 亿美元。这一重要的战略举动旨在通过整合 Cullgen 的靶向蛋白质降解平台和相关资产来增强 Gyre 的产品线和能力。考虑到 Gyre 的市值，这一收购代表了其治疗重点和潜在未来收入流的重大扩张。虽然全股票交易的性质表明可能会导致现有股东的股权稀释，但添加新的、先进的平台对于长期增长是一个强大的正面因素。交易者将监测整合过程和新收购的产品线资产的进展。

在该公告发布时，GYRE的交易价格为$7.60，交易所为NASDAQ，所属行业为Life Sciences，市值约为$7.5亿。 52周交易区间为$6.11至$13.75。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed GYRE - Latest Insights

GYRE
Apr 27, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Shareholders to Vote on Significant Stock Issuance for $300M Cullgen Acquisition
Sentiment: Neutral
View Wiseek Article
GYRE
Apr 16, 2026, 4:13 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Shareholder Vote Sought for Cullgen Merger-Related Preferred Stock Conversion, Enabling Significant Dilution
Sentiment: Neutral
View Wiseek Article
GYRE
Mar 23, 2026, 7:51 AM EDT
Filing Type: 8-K
Importance Score:
8
GYRE Subsidiary Submits New Drug Application for Lead Candidate F351 (Hydronidone) in China
Sentiment: Positive
View Wiseek Article
GYRE
Mar 13, 2026, 4:31 PM EDT
Filing Type: 10-K
Importance Score:
8
Annual Report Highlights Strong Pipeline Progress, Strategic Acquisition, and Capital Infusion
Sentiment: Positive
View Wiseek Article
GYRE
Mar 12, 2026, 6:31 AM EDT
Filing Type: 8-K
Importance Score:
7
Gyre Therapeutics Details Significant Revenue Potential for F351 and Cullgen Pipeline Progress at Investor Conference
Sentiment: Positive
View Wiseek Article
GYRE
Mar 12, 2026, 6:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Gyre Therapeutics Forecasts 2026 Revenue of $100.5M-$111M
Sentiment: Neutral
View Wiseek Article
GYRE
Mar 11, 2026, 8:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Gyre Therapeutics Projects 2026 Revenue Decline, Formalizing Guidance After Q4 2025 Results
Sentiment: Negative
View Wiseek Article
GYRE
Mar 02, 2026, 9:24 AM EST
Filing Type: 8-K
Importance Score:
9
Gyre Therapeutics to Acquire Cullgen for $300M in All-Stock Deal, Expanding Pipeline and Announcing New CEO
Sentiment: Neutral
View Wiseek Article
GYRE
Mar 02, 2026, 8:29 AM EST
Source: Reuters
Importance Score:
9
Gyre Therapeutics to Acquire Cullgen for $300M All-Stock Deal, Adding Protein Degradation Platform
Sentiment: Positive
View Wiseek Article
GYRE
Jan 05, 2026, 7:06 AM EST
Filing Type: 8-K
Importance Score:
8
Gyre Therapeutics' Hydronidone Cleared for Conditional Approval Pathway, Priority Review in China
Sentiment: Positive
View Wiseek Article